Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme

Showing 521 to 530 of 1974

TitleReference numberPublishedLast updated
Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancerTA801
Cemiplimab for treating advanced cutaneous squamous cell carcinomaTA802
Multiple sclerosis in adults: managementNG220
Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiationTA798
Reducing sexually transmitted infectionsNG221
Venetoclax for treating chronic lymphocytic leukaemiaTA796
Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer (terminated appraisal)TA797
Preterm labour and birthNG25
Gout: diagnosis and managementNG219
Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus (terminated appraisal)TA793

Results per page

  1. 10
  2. 25
  3. 50
  4. All